Related Experiment Video
Updated: Nov 20, 2025
Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
Published on: March 6, 2019
Preparation of Site-Specific Cytotoxic Protein Conjugates via Maleimide-thiol Chemistry and Sortase A-Mediated
Mateusz Adam Krzyscik1, Aleksandra Sokolowska-Wedzina2, Karolina Jendryczko2
1Department of Protein Engineering, Faculty of Biotechnology, University of Wroclaw; Department of Protein Biotechnology, Faculty of Biotechnology, University of Wroclaw.
Abstract:
Cancer is currently the second most common cause of death worldwide. The hallmark of cancer cells is the presence of specific marker proteins such as growth factor receptors on their surface. This feature enables development of highly selective therapeutics, the protein bioconjugates, composed of targeting proteins (antibodies or receptor ligands) connected to highly cytotoxic drugs by a specific linker. Due to very high affinity and selectivity of targeting proteins the bioconjugates recognize marker proteins on the cancer cells surface and utilize receptor-mediated endocytosis to reach the cell interior. Intracellular vesicular transport system ultimately delivers the bioconjugates to the lysosomes, where proteolysis separates free cytotoxic drugs from the proteinaceous core of the bioconjugates, triggering drug-dependent cancer cell death. Currently, there are several protein bioconjugates approved for cancer treatment and large number is under development or clinical trials. One of the main challenges in the generation of the bioconjugates is a site-specific attachment of the cytotoxic drug to the targeting protein. Recent years have brought a tremendous progress in the development of chemical and enzymatic strategies for protein modification with cytotoxic drugs. Here we present the detailed protocols for the site-specific incorporation of cytotoxic warheads into targeting proteins using a chemical method employing maleimide-thiol chemistry and an enzymatic approach that relies on sortase A-mediated ligation. We use engineered variant of fibroblast growth factor 2 and fragment crystallizable region of human immunoglobulin G as an exemplary targeting proteins and monomethyl auristatin E and methotrexate as model cytotoxic drugs. All the described strategies allow for highly efficient generation of biologically active cytotoxic conjugates of defined molecular architecture with potential for selective treatment of diverse cancers.
Insights
Developing targeted cancer therapies, protein bioconjugates link cytotoxic drugs to targeting proteins for selective cancer cell death. This study details site-specific chemical and enzymatic methods for creating these advanced cancer therapeutics.
Area of Science:
- Biotechnology
- Oncology
- Medicinal Chemistry
Background:
- Cancer is a leading global cause of death, necessitating innovative therapeutic strategies.
- Protein bioconjugates, combining targeting proteins with cytotoxic drugs, offer selective cancer cell targeting via receptor-mediated endocytosis.
- A key challenge in bioconjugate development is the site-specific attachment of drugs to targeting proteins.
Purpose of the Study:
- To present detailed protocols for site-specific drug incorporation into targeting proteins for cancer therapy.
- To evaluate chemical (maleimide-thiol) and enzymatic (sortase A) ligation strategies.
- To demonstrate the generation of biologically active, site-specifically conjugated protein bioconjugates.
Main Methods:
- Utilized maleimide-thiol chemistry for site-specific drug conjugation.
- Employed sortase A-mediated ligation for enzymatic drug attachment.
- Used engineered fibroblast growth factor 2 and IgG Fc fragments as targeting proteins.
- Incorporated monomethyl auristatin E and methotrexate as model cytotoxic drugs.
Main Results:
- Successfully demonstrated site-specific incorporation of cytotoxic drugs into targeting proteins using both chemical and enzymatic methods.
- Generated protein bioconjugates with defined molecular architecture and high biological activity.
- Validated the potential of these strategies for developing selective cancer therapeutics.
Conclusions:
- Site-specific conjugation strategies, both chemical and enzymatic, are highly efficient for generating potent protein bioconjugates.
- These methods enable the creation of precisely engineered cancer therapeutics with potential for treating diverse cancers.
- Advancements in conjugation chemistry are crucial for the future development of targeted cancer therapies.
